Frankfurt
02.09.25 | 08:04
0,077 Euro
+5,08 % +0,004
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,103 | 0,106 | 02.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 219 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 28.07. | Mauna Kea Technologies Reports First Half 2025 Revenue | 387 | Business Wire | On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2 Record U.S. sales productivity despite ongoing safeguard procedure Total revenue down 5% amid weaker EMEA and... ► Artikel lesen | |
| 24.07. | Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership | 416 | Business Wire | Leveraging strong momentum for the CellTolerance® application, Mauna Kea Technologies is expanding into new geographies with high growth potential Regulatory clearance in Australia (TGA) expected... ► Artikel lesen | |
| 21.07. | Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S. | 562 | Business Wire | 14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property An ecosystem built around the Cellvizio® platform, enabling partners to develop advanced... ► Artikel lesen | |
| 15.07. | Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio | 470 | Business Wire | Clinical team at Stanford Health Care achieved the CellTolerance 100-case milestone with the Cellvizio® platform in less than 6 months The CellTolerance® test offers IBS patients a way to detect... ► Artikel lesen | |
| 10.07. | Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure | 742 | Business Wire | Bridge financing through the issuance of convertible bonds to Vester Finance and European investors for €1.8m Immediate receipt of the entire financing upon signing Cash runway extended to... ► Artikel lesen | |
| 10.07. | Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure | 445 | Business Wire | Structuring of financing in progress to secure the safeguard period and support long-term development plan Authorization to implement the classes of affected parties proceeding, paving the way... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 07.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 260 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.06. | Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025 | 497 | Business Wire | All the resolutions proposed by the Board of Directors were adopted
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and... ► Artikel lesen | |
| 05.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 351 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 02.06. | Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification | 510 | Business Wire | Cellvizio technology combined with AI outperforms human experts in pancreatic cyst risk stratification, a major breakthrough for patient management Results build on new CLIMB study data recently... ► Artikel lesen | |
| 21.05. | Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress | 439 | Business Wire | Ongoing Strategic Negotiations Towards a Licensing Agreement Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers of Excellence Adopting the Technology, Including a... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 5, 2025 and the Instructions for Participation | 1.122 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 06.05. | Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week 2025 | 908 | Business Wire | Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on the diagnosis and treatment of pancreatic cystic lesions... ► Artikel lesen | |
| 05.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 712 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2024 Annual Financial Report | 826 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio in Key Indications | 470 | Business Wire | Pancreatic cyst abstracts build on endorsement of Cellvizio by Europe's leading endoscopy society, ESGE, as a key tool for improving pancreatic cyst diagnostic accuracy AI, pancreatic cancer... ► Artikel lesen | |
| 24.04. | Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update | 960 | Business Wire | Commercial activities remain strong, including CellTolerance launch Recently approved safeguard proceeding yielding productive creditor and investor discussions aimed at strengthening Mauna Kea's... ► Artikel lesen | |
| 07.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 331 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF Listing: Euronext Growth Paris
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing:... ► Artikel lesen | |
| 01.04. | Mauna Kea Technologies Announces Entrance Into Exclusive Negotiations for a Licensing Agreement for Cellvizio in an Important Therapeutic Area With a Major Industry Player | 530 | Business Wire | The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,112 | +1,82 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| FAMICORD | 6,600 | -2,22 % | EQS-News: FamiCord AG steigert Umsatz und Ergebnis im ersten Halbjahr 2025 deutlich und verlagert Fokus zukünftig noch stärker auf Kerngeschäft | EQS-News: FamiCord AG
/ Schlagwort(e): Halbjahresergebnis/Halbjahresbericht
FamiCord AG steigert Umsatz und Ergebnis im ersten Halbjahr 2025 deutlich und verlagert Fokus zukünftig... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,100 | 0,00 % | Geratherm Medical AG: Starkes Wachstum im ersten Halbjahr und operatives Break-even; KAUFEN bestätigt. | Geratherm verzeichnete im ersten Halbjahr 2025 ein starkes Wachstum: Die vergleichbaren Umsätze stiegen um 13,2 % gegenüber dem Vorjahr und sequenziell um 15,4 %. Getrieben wurde dieses Wachstum von... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,427 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria | HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,648 | -1,82 % | RedChip Companies, Inc.: NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FL / ACCESS Newswire / August 29, 2025 / RedChip Companies will air interviews with NioCorp Developments Ltd. (Nasdaq:NB) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks... ► Artikel lesen | |
| MEDICLIN | 2,980 | -3,87 % | EQS-News: MEDICLIN AG: MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025
31.07.2025 / 13:13 CET/CEST
Für... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update | -- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter --
-- Evofem Advances Plans for Special Meeting of Stockholders to Approve... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Aktionäre von Sonoma Pharmaceuticals stimmen allen Anträgen auf der Hauptversammlung zu | ||
| VERU | 3,270 | 0,00 % | VERU INC. - 8-K, Current Report | ||
| LIFEWARD | 0,617 | -2,73 % | Lifeward Ltd.: Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| LIGHT AI | 0,142 | +2,90 % | Light AI reports Financial Results for Three and Six Months ended June 30, 2025 | ||
| MAVEN BRANDS | 0,001 | 0,00 % | Maven Brands Inc: Maven Brands to sell subdivided Lumby land for $3.5M | ||
| EKSO BIONICS | 3,950 | 0,00 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,700 | -5,31 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 46,260 | -3,02 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,004 (+5,08 %) liegt der Kurs bei 0,077 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.